- Location
pharmacokinetic
"-
High Doses of Vitamin C Helped Kill Cancer Cells
Feb 25, 2014Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some ...
-
NAMPA Reminds Consumers of The Important Scientific Evidence Released in 2013
Dec 23, 2013The North American Metal Packaging Alliance, Inc. (NAMPA) reminds consumers of the important scientific evidence released in 2013 that supports the safety of Bisphenol A (BPA) in food contact applications. Data from key studies, including ...
-
Certara Partnered with LabLogic Systems to Integrate Phoenix Winnonlin PK/PD Modeling
Dec 12, 2013Certara, a provider of software and scientific consulting services, has partnered with LabLogic Systems to integrate Certara’s Phoenix WinNonlin pharmacokinetic (PK)/pharmacodynamic (PD) modeling and non-compartmental analysis product ...
Tags: Lablogic Systems, Drug Discovery
-
Auxilium Pharmaceuticals, a biopharmaceutical company, has obtained an approval
Dec 6, 2013The US Food and Drug Administration (FDA) has granted orphan drug status for Kinex Pharmaceuticals' dual src/pre-tubulin inhibitor 'KX02' for the treatment of gliomas, which are the most common and aggressive form of brain cancer. KX02 is ...
Tags: Orphan Drug, Medicine
-
Baxter Filed an Amended BLA to Re-Start Review Process to Treat Adult Patients with PI
Dec 5, 2013Baxter International has filed an amended biologics license application (BLA) to the US Food and Drug Administration (FDA) to re-start the review process for approval of HyQvia facilitated subcutaneous infusion to treat adult patients with ...
-
FDA Has Approved Merck's Noxafil 100 Mg Delayed-Release Tablets.
Nov 29, 2013The US Food and Drug Administration (FDA) has approved Merck's Noxafil (posaconazole) 100 mg delayed-release tablets. The tablets are a new formulation with a loading dose of 300mg (three 100mg delayed-release tablets) twice daily on the ...
-
A.P. Pharma Has Initiated a Program to Expand Its Pipeline of Sustained Release Products
Nov 14, 2013A.P. Pharma, a specialty pharmaceutical company, has initiated a program to expand its pipeline of sustained release products, including a new program targeting the relief of post-surgical pain. The company also announced it will pursue a ...
Tags: A.P.Pharma, Pipeline Expansion
-
Firm Zogenix Entered Into a Development and Option Agreement (D&O Agreement) with Altus
Nov 6, 2013US-based pharmaceutical firm Zogenix has entered into a development and option agreement (D&O Agreement) with Altus Formulation (Altus) to develop abuse deterrent formulations of Zohydro ER (hydrocodone bitartrate) extended-release ...
Tags: Zogenix, Zohydro ER
-
Pulmatrix Has Released Positive Results From Initial Stage of Phase IB Clinical Trial
Oct 31, 2013Pulmatrix has released positive results from initial stage of Phase IB clinical trial of a bronchodilator therapy PUR0200 for patients with chronic obstructive pulmonary disease (COPD). The company said PUR0200 is the first small molecule ...
-
Janssen Has Submitted a Marketing Authorization Application to EMA
Oct 17, 2013Janssen-Cilag (Janssen) has submitted a marketing authorization application to the European Medicines Agency (EMA) for the approval of a once-daily fixed-dose antiretroviral combination tablet of HIV-1 medicine darunavir with cobicistat. ...
Tags: European Marketing, HIV-1
-
Protalix BioTherapeutics Has Announced Initial Positive Results From Oral GCD
Oct 16, 2013Israeli pharmaceutical company Protalix BioTherapeutics has announced initial positive results from its Phase I clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112), in patients with Gaucher disease. In the trial, oral ...
-
FDA Has Accepted to Review AstraZeneca's New Drug Application for Epanova
Sep 20, 2013The US Food and Drug Administration (FDA) has accepted to review AstraZeneca's new drug application (NDA) for Epanova, an investigational compound for the treatment for patients with severe hypertriglyceridaemia. Omthera Pharmaceuticals, ...
-
Certara Signed a Research Agreement with The Hamner Institutes for Health Sciences
Aug 22, 2013Software and scientific consulting services provider Certara has signed a research agreement with The Hamner Institutes for Health Sciences, to explore the scientific benefits of using its Simcyp Simulator to drive hepatic drug exposure ...
-
ViiV Has Announced The FDA Approval of an Integrase Inhibitor,Tivicay 50mg Tablets
Aug 15, 2013ViiV Healthcare, HIV company established by GlaxoSmithKline and Pfizer, has announced the FDA approval of an integrase inhibitor, Tivicay (dolutegravir) 50mg tablets, for the treatment of HIV-1. Tivicay is indicated for use in combination ...
Tags: Viiv Healthcare, HIV-1
-
USPTO Has Issued The US Patent Covering Cerecor's Antitussive, FP01
Aug 13, 2013The US Patent and Trademark Office (USPTO) has issued the US patent covering Cerecor's antitussive, FP01, a unique formulation of memantine hydrochloride. The patent protects composition of lozenge, which provides a dual mechanism of ...
Tags: FP01 Antitussive, USPTO
